Furiex Pharmaceuticals VP Unloads $300,497 in Stock (FURX)
Furiex Pharmaceuticals (NASDAQ:FURX) VP Paul S. Covington sold 2,872 shares of the stock on the open market in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $104.63, for a total value of $300,497.36. Following the completion of the transaction, the vice president now directly owns 25,751 shares of the company’s stock, valued at approximately $2,694,327. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Furiex Pharmaceuticals (NASDAQ:FURX) traded down 0.34% on Thursday, hitting $104.63. 331,694 shares of the company’s stock traded hands. Furiex Pharmaceuticals has a one year low of $32.05 and a one year high of $121.97. The stock’s 50-day moving average is $102.1 and its 200-day moving average is $77.80. The company’s market cap is $1.131 billion.
Furiex Pharmaceuticals (NASDAQ:FURX) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.25) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.63) by $0.62. The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $10.01 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was down 83.7% on a year-over-year basis. On average, analysts predict that Furiex Pharmaceuticals will post $-2.57 earnings per share for the current fiscal year.
Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.